We recently published 10 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s radar ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Shares rose 5% for Novo Nordisk on the approval of oral Wegovy as it looks to ease market pressures with a significant ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron offers super weight-loss maintenance. Read more here.

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

A pill version of weight-loss drug Wegovy will be manufactured in the Triangle and could be available within weeks after the ...

The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

The Food and Drug Administration has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for ...

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...